FDA’s Guide For Selectively Collecting Safety Data
Executive Summary
A recent draft guidance reflects the agency’s views on when it may be appropriate to reduce the amount of safety information collected in late-stage and post-marketing studies and what types of data may be eligible for limited or non-collection.
You may also be interested in...
Large Simple Trials Need FDA Boost, IoM Report Says
“Clear specific guidance” from the agency would help close the perception gap between what types of data industry thinks FDA wants and what the agency actually expects, according to a summary of a 2012 Institute of Medicine workshop.
FDA Oncology Panel To Weigh Independent Review Of PFS Event Subset
The Oncologic Drugs Advisory Committee’s July 24 meeting to discuss the merits of independent radiological review of progression assessments in a pre-specified subgroup of patients, instead of 100% of all assessments, comes three years after the agency signaled it was open to considering such an approach.
Targeted Safety Data Collection Needs International Agreement, Industry Tells FDA
FDA’s proposal to limit collection of certain safety data in late-stage and post-marketing clinical trials will only reduce the burden on sponsors, investigators and patients if drug regulators across the globe agree to the concept, pharmaceutical manufacturers say.